The FDA has granted Fast Track designation to pevifoscorvir sodium, an oral capsid assembly modulator for chronic HBV.
Screening is planned to begin in April 2026, with enrolment completion expected by the end of the first quarter of 2027.
One of the most fundamental questions in biology is how a single fertilized egg produces the diverse cell types making up the body – from neurons and skin to muscle and blood – that bear the same ...
HIV franchise still drives growth, oncology M&A faces skepticism, & valuation looks cheap at ~16x P/E. Click for this GILD ...
Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that the independent Data ...
Genome‑wide CRISPR screens in primary human T cells reveal human genes that promote or block HIV infection, uncovering potent ...
Zacks Investment Research on MSN
Bristol Myers vs Gilead Sciences: Which biotech stock is a better bet now?
Bristol Myers Squibb BMY and Gilead Sciences GILD are two leading biotech players with diversified portfolios and a strong ...
The positive rabies case is the second New Mexico has seen in the last ten months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results